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Background: Older people represent a significant proportion of patients admitted to hospital. Their care compared
to younger patients is more challenging, length of stay is longer, risk of hospital-acquired problems higher and the
risk of being re-admitted within 28 days greater. This study aims to compare a Community In-Reach and Care
Transition (CIRACT) service with Traditional Hospital Based rehabilitation (THB-Rehab) provided to the older person.
The CIRACT service differs from the THB-rehab service in that they are able to provide more intensive hospital
rehabilitation, visiting patients daily, and are able to continue with the patient’s rehabilitation following discharge
allowing a seamless, integrated discharge working alongside community providers. A pilot comparing the two
services showed that the CIRACT service demonstrated reduced length of stay and reduced re-admission rates
when analysed over a four-month period.
Methods/Design: This trial will evaluate the clinical and cost-effectiveness of the CIRACT service, conducted as a
randomised controlled trial (RCT) with an integral qualitative mechanism and action study designed to provide the
explanatory and theoretical components on how the CIRACT service compares to current practice. The RCT element
consists of 240 patients over 70 years of age, being randomised to either the THB therapy group or the CIRACT
service following an unplanned hospital admission. The primary outcome will be hospital length of stay from admission
to discharge from the general medical elderly care ward. Additional outcome measures including the Barthel Index,
Charlson Co-morbidity Scale, EuroQoL-5D and the modified Client Service Receipt Inventory will be assessed at the
time of recruitment and repeated at 91 days post-discharge. The qualitative mechanism and action study will involve a
systematic programme of organisational profiling, observations of work processes, interviews with key informants and
care providers and tracking of participants. In addition, a within-trial economic evaluation will be undertaken comparing
the CIRACT and THB-rehab services to determine cost-effectiveness.
Discussion: The outcome of the study will inform clinical decision-making, with respect to allocation of resources
linked to hospital discharge planning and re-admissions, in a resource intensive and growing group of patients.
Trial registration: Registered with the ISRCTN registry (ISCRCTN94393315) on 25 April 2013 (version 3.1, 11
September 2014).
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The number of people aged 70 years and over in the
United Kingdom is expected to double by 2025 [1], with
an associated increase in the proportion of unplanned
medical admissions in this age group over the next
10 years [2]. Many of these patients have multiple co-
morbidities. These include poly-pharmacy, cognitive def-
icits and physical impairments which makes their care,
management and timely discharge from hospital com-
plex. This often prolongs length of stay and increases
28 day re-admission rates in older patients when com-
pared to their younger counterparts [3].
Nationally, over the last six years, length of stay has
reduced but 28 day re-admission rates have increased
from 11 to 14% [4]. In Nottingham, between 2010 and
2013 the mean length of stay across the medical elderly
care wards (five wards, 6,924 patients) decreased from
14 to nine days, but 28 day re-admission rates increased
from 14 to 19% (Sahota and Fleming, 2013, unpublished
data). The reasons for these readmissions are multi-
factorial. Patients are often unprepared for their self-
management role in the next care setting [5] and are
often unable to reach an appropriate healthcare practi-
tioner who has access to their discharge summary when
problems arise [6-8]. There simply may not be appropri-
ate resources in the community to respond to the needs
of these patients in a responsive manner, placing them at
risk of readmissions. Furthermore, patient safety is often
compromised during this vulnerable period, with high
rates of medication errors [9-12], incomplete or inaccur-
ate information on transfer [13] and lack of appropriate
follow-up care [14], collectively leading to fragmented
discharge planning and increased rates of recidivism to
high intensity care settings when patients’ care needs are
not met [15]. This increases health and social care costs,
which will be further exacerbated by government plans
to reduce funding if patients are re-admitted as an emer-
gency within 28 days of being discharged [16].
In England and Wales, to address the problem of rising
re-admission rates, the Department of Health has allocated
£300 million in 2014, as part of the ‘funding for re-
ablement linked to the hospital discharge’ funding stream
[17]. This money is to be spent on developing local plans in
conjunction with the Local Authority, Foundation Trusts
and NHS Trusts and Community Health services, to facili-
tate seamless care for patients on discharge from hospital
and prevent avoidable hospital readmissions. Some Clinical
Commissioning Groups (CCGs) have invested in ‘early sup-
ported discharge at home’ schemes, some into ‘community-
based rehabilitation’ schemes and some have invested very
little at all. Reviews of the literature suggest that it is cur-
rently unclear which is the most effective and efficient
structure and organisation of community and intermediate
care services in relation to their purpose [18,19].We undertook a structured literature review to identify
systematic and Cochrane reviews of ‘early supported dis-
charge’, ‘discharge planning from hospital to home’ and
‘care transition’ interventions [5,10,18-23]. The key com-
ponents in the successful RCTs of high methodological
quality were then identified as more intensive rehabilita-
tion, working closer with the patient and their relatives
and facilitating ‘care transition’ back into community,
informing the frequency and duration of the service
intervention.
This was followed by a series of multi-perspective
focus group meetings with service users, experienced
healthcare professionals and service managers. The key
aims and objectives of these meetings were to identify
the make-up of the team and the delivery of the inter-
vention. Important areas identified the need for generic
rehabilitation staff, a dedicated allied healthcare ‘transi-
tion coach’ and senior leadership and governance within
the team.
The ‘care transition model’ has been proposed as a
model to address potential threats to patient quality and
safety during care transition [22], and has been shown to
reduce early hospital re-admission rates [5]. Care transi-
tion is defined as a set of actions ensuring the coordin-
ation and continuity of care as patients transfer between
different locations. These include logistical arrange-
ments, education of the patient and family and coordin-
ation among the health professionals involved in the
transition essential for persons with complex care needs.
Key to this model is a home visit, ideally within 48 to
72 hours after hospital discharge. The aim of the visit is
to ensure that the patient has received appropriate
services and equipment, coordinate communication be-
tween primary and secondary care and review the pa-
tient’s goals established on discharge from hospital.
Provision for elderly medical inpatients in Nottingham
takes two forms. One consists of the Traditional Hos-
pital Based multidisciplinary rehabilitation (THB-rehab)
service, referring the patient on to different community
rehabilitation and social services on discharge. The other
is a pilot Community In-Reach rehabilitation and Care
Transition (CIRACT) service, consisting of a senior oc-
cupational therapist, senior physiotherapist, social ser-
vices practitioner and an assistant practitioner, working
more closely across multiple boundaries with patients
and their carers. The CIRACT intervention is set apart
from other models of care as although the team is based
on the hospital ward, they are employed by a community
NHS provider (NHS Nottingham City Care Partnership),
and therefore are able to bring their community expert-
ise into the hospital care setting, bridging the gap be-
tween the community and hospital settings. In addition,
the CIRACT service aims to i) provide intensive rehabili-
tation; ii) work closely with the patient, relatives and
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facilitate and access a wider range of care and services in
the community and iii) provide a community follow-up
service.
Pilot data suggest that compared to the THB-rehab
service, the CIRACT service can reduce median length
of stay and 28 day re-admission rates, over a four-month
period. However the clinical and cost-effectiveness of
the service needs to be evaluated in a randomised trial.
Objectives
The primary objective of the CIRACT trial is to assess
whether length of hospital stay for unplanned hospital
admission among people aged 70 years or older allocated
to receive the CIRACT service is different compared
with the THB-rehab. The secondary objectives include
assessing the effects of the CIRACT service on re-
admission rates within 28 days post-discharge; super
spell bed days (total time in NHS care); patient function
and patient health-related quality of life. Alongside this,
the qualitative part of the trial aims to investigate the de-
sign and delivery of the CIRACT service and assess ser-
vice user experiences of the two forms of rehabilitation
delivery. The health economics part of the study aims to
evaluate the cost-effectiveness of the CIRACT service
compared to the THB-rehab service.
Trial design
The study is a single-centre pragmatic parallel randomised
controlled trial with an integral qualitative mechanism
and action study and health economic study. Participants
will be followed-up to 91 days post-discharge.
Methods/Design
The initial part of the study including recruitment, treat-
ment allocation and in-patient rehabilitation will take
place on the acute hospital ward. Follow-up data will be
collected via a telephone interview with the participant
or personal consultee in their own home.
Study setting
Any patient admitted to the hospital from the medical ad-
missions unit to one of the three acute, general medical
elderly care wards at the Queen’s Medical Centre (1,800
beds serving a population of 680,000), Nottingham, United
Kingdom will be screened for inclusion into the trial.
Eligibility criteria
Participants will be eligible for the study if all of the in-
clusion and none of the exclusion criteria are met.
Inclusion criteria
The inclusion criteria are as follows:1. aged 70 years and over,
2. have been admitted to hospital on the general
medical elderly care ward as an unplanned
admission,
3. have been admitted to hospital from their own
home or residential care home and
4. have their registered GP within the Nottingham City
CCG catchment area.Exclusion criteria
The exclusion criteria are as follows:
1. were bed bound prior to admission or moribund on
admission,
2. are receiving palliative care,
3. were previously included in the trial on an earlier
admission or
4. are not able to be screened and recruited by the
Research Assistant (RA) within 36 hours of
admission to the study ward. A 36-hour deadline en-
sures there is not a delay to the participant receiving
therapy, and will enable the recruitment of a large
proportion of patients admitted over a weekend,
when no RA will be available recruit.Study intervention
Each participant will be randomly allocated to the CIR-
ACT service (intervention arm) or THB-rehab (control
arm). The CIRACT team will conduct an assessment of
the participant’s ability to perform certain tasks within
24 hours of randomization, enabling the formulation of
a comprehensive rehabilitation plan. The CIRACT team
will consist of a physiotherapist, an occupational therap-
ist and a community care officer who will be employed
by Nottingham CityCare, but will be based on one of the
study wards. While in hospital the participants will be
treated daily (seven days a week, if appropriate) by the
CIRACT team and the time of rehabilitation they receive
will be dependent on their needs. During the partici-
pant’s hospital stay the CIRACT team will liaise with the
participant and their carer(s) to visit the participant’s
home to assess and provide recommendations for equip-
ment and make adaptations and/or modifications if re-
quired. The CIRACT service will utilise the teams’
expertise in community working to form links with the
appropriate services to ensure a smooth and effective
discharge. In more complex cases the CIRACT team will
take the participant out of the hospital for a home visit
prior to discharge. Following discharge, the CIRACT
team will visit the participant at home within 48 hours
of discharge to assess the level of rehabilitation required
at home, and the CIRACT team will undertake further
follow-up visits as deemed necessary.
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based therapy teams on weekdays only as a control group
receiving ‘usual care’. Members of these teams will jointly
conduct an assessment of the participant’s ability to per-
form certain tasks and provide recommendation for
rehabilitation. The ward team will refer the participant
to the appropriate community-based services for the
provision of equipment at home, personal care and on-
going rehabilitation where appropriate at discharge. Once
discharged from hospital, the patient will have no contact
with the ward rehabilitation staff.
In either group, if a participant becomes medically un-
well at any point to the extent they are no longer able to
undertake therapy (as directed by the ward doctor), the
treating team will withhold further therapy until being
instructed by the ward doctor it is safe to recommence
therapy. The nursing and medical care provided by the
ward staff will not differ between the two groups.
Primary outcome measures
The primary outcome is hospital length of stay from
randomisation to discharge from a general medical eld-
erly care ward. The date of randomisation will be used
instead of date of admission to the ward to negate for
the impact of a delay in randomisation and reduce the
risk of cross contamination.
Secondary outcome measures
The secondary outcome measures are:
1. Super spell bed days (total time in NHS care
including hospital care and intermediate care) from
admission to 91-day follow-up.
2. Unplanned re-admission rates at day 28 and day 91.
Days 28 and 91 were selected as they are the
commissioners’ targets for re-admission.
3. The Barthel ADL index [24] at baseline and at
91 days post-discharge to assess activities of daily
living (ADL) and mobility.
4. EQ-5D-3 L health-related quality of life measure
[25] at baseline and at 91 days post-discharge. The
EQ-5D-3 L is a standardized measure of quality of
life looking at mobility, self-care, usual activities,
pain and/or discomfort and anxiety and/or
depression.
5. The Charlson comorbidity index [26] at baseline and
at 91 days post-discharge to assess comorbidity. The
Charlson codes a total of 22 comorbid conditions
into a single score.
6. The mean cost per patient of CIRACT and THB-
rehab will be estimated using micro-costing
methods.
7. The modified Client Service Receipt Inventory
(CSRI) questionnaire [27] at baseline and at 91 dayspost-discharge. The CSRI is a cost questionnaire
designed to measure and compare the service cost
of both rehabilitation services.
The RA will collect demographic data (including age,
sex, reason for admission and living circumstances) and
outcome measures via face-to-face interviews on trial
entry, and via a telephone interview at the three-month
follow-up assessment. The RA will be blinded to treat-
ment allocation. The time schedule of enrolment, inter-
ventions, assessments and visits for participants is
shown in Additional file 1 and the trial flow diagram is
presented in Figure 1.
Sample size calculation
The primary statistical analysis will compare length of
hospital stay for those allocated to receive the CIRACT
service versus the THB-rehab service. Pilot data showed
the log transformed length of stay to be normally distrib-
uted, with a standard deviation of 0.9. Therefore, 111 pa-
tients per arm will be required for analysis in order to
detect a clinically important effect size of three days
(equivalent to a ratio of geometric means of 0.7) with two-
sided alpha of 5% and 80% power. Allowing for 5% non-
collection of primary outcome data, 240 patients in total
will be randomised following an acute unplanned admis-
sion to hospital over a 13-month recruitment period.
Recruitment and consent
All eligible participants will be made aware of the trial at
the time of admission and invited to participate in the
trial. Written informed consent will be obtained by the
RA in accordance with the International Conference on
Harmonisation Guidelines for Good Clinical Practice
(ICH GCP) [28]. In patients who are confused (dementia
or delirium such that the subject cannot understand the
nature of consenting to a research study and the study
process), consent will be obtained by carers or other prox-
ies including staff, following the established framework of
Berghmans and Ter Meulen [29], used in previous ethic-
ally approved studies in older persons with dementia.
Randomisation procedure
Once the RA has gained consent from the participant, sub-
jects will be allocated to the CIRACT service or the trad-
itional hospital rehabilitation service (control) arm using
the web-based randomisation service provided by the
Clinical Trials Support Unit, University of Nottingham.
Randomisation will be determined by a computer-
generated pseudo-random code using random permuted
blocks of randomly varying size, created by the Nottingham
Clinical Trials Unit (CTU), in accordance with their stand-
ard operating procedure (SOP) and held on a secure server.
Participants will be allocated with equal probability to
Figure 1 Trial flow diagram. Shaded areas represent parts of the study which do not have participant involvement. CCI = Charlson Comorbidity
Index, CIRACT = Community In-Reach and Care Transition, CSRI = Client Services Record Inventory, EQ-5D-3 L = EuroQol-5 dimension-3 Level
quality of life scale, MMSE =Mini Mental State Examination, THB-Rehab = Traditional Hospital Based Rehabilitation.
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quested through a PC with internet explorer and internet
access. The system is located on a dedicated secure server
within the University of Nottingham. All communications
between the user's PC and the server will be fully encrypted
(secured SSL 128-bit encrypted) and via a unique username
and password.
Blinding
The RA collecting data and the research team analysing
the data will be blinded to treatment allocation. The par-
ticipant and ward staff will not be blinded to treatment
allocation as the treating therapists will be liaising
closely with ward staff to ensure optimal patient care.
The three-month follow-up data will be collected by an
RA blinded to treatment allocation.
Qualitative, implementation and action study
The qualitative, implementation and action study aims to
understand the situated activities and interactions that
constitute the CIRACT service in comparison to THB-
rehab service, and to understand how these mechanics of
care interact with other factors located in the wider care
system. This will investigate how the service is perceived
by all participants in terms of transitional planning,effective therapy delivery and the general organisational
aspects in relation to the concurrent services provided
within the research wards.
The qualitative appraisal also draws upon recent devel-
opments in the field of implementation science. It is
widely recognised that new interventions or ways of
working do not easily move from policy into practice,
but are transformed and even inhibited by the contexts
into which change is desired, especially professional
boundaries [30]. Recent developments in implementation
science have led to new approaches for understanding this
process, such as the Promoting Action on Research Im-
plementation in Health Services (PARIHS) framework and
Normalisation Process Theory. This appraisal of CIRACT
was informed by Damschroder et al.’s [31] consolidated
framework. This draws attention to a range of key factors
that frame and are involved in the implementation of new
practices including:
1. Characteristics of the intervention itself.
2. The outer and inner context (outer context referring
to the wider institutional, political and social
environment, with the inner context referring to the
internal organisational environment where change is
to be made).
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context including their sense-making, mind-sets,
cultures and networks.
A range of behavioural theories inform analysis of indi-
vidual behaviours, but this study adopts a socio-cultural
practice perspective that considers how social practices
are embedded within wider social and cultural fields of in-
fluence, whilst allowing for individual agency. This is espe-
cially relevant in healthcare settings given the influence of
professional cultures and boundaries on practices. The
final aspect is the implementation processes itself which
cuts through involves the above factors. The model also
suggests that implementation is non-linear and can cut
across organisational and practice levels.
Nested qualitative appraisal
The aim of the qualitative, implementation and action
study is to understand how the two forms of rehabilita-
tion service (CIRACT service and THB-rehab service)
are delivered as a complex intervention in older patients.
In considering the implementation, organisation and de-
livery of CIRACT, this model draws analytical attention
to: i) the nature of CIRACT including how it is config-
ured, disseminated and translated into practice settings;
ii) the role of wider changes within the organisation and
delivery acute and community care, including wider polit-
ical issues, financial and regulatory issues; iii) the influence
of local organising factors such as resources and staffing,
modes of working and professional boundaries and iv) the
role of local actors, especially CIRACT and ward staff, but
also patients and carers.
This will involve three linked activities (A to C), linked
to three research techniques (D to F).
A. Each rehabilitation service will be described and
analysed to understand the local context factors that
might shape service delivery, including staffing and
resource levels, participant group type and
variability, provision of support services, service
culture, receptivity to change and team/and
professional work dynamics.
B. In a purposive selection of participants, the
organisation and delivery of the intervention will be
described and analysed in-depth to understand how
the service is configured and how therapy is planned
and delivered.
C. The views and experiences of professionals and
participants at each participating site will be
described and analysed to understand their
involvement in, reactions to and continued use of
both forms of rehabilitation.
D. Organisational profiling: involving a relatively
standardised checklist pro forum of knowncontextual and organisational variables known to
influence implementation of change and the delivery
of complex intervention. This will be completed
through focussed visits, guided tours and key
stakeholder interviews. These will be undertaken
over a two to three day period and recorded using a
standard form to facilitate rapid data analysis and
comparison.
E. More detailed observations of service organisation
and delivery over a period of three to four weeks
within a purposive selection of participants. This
will be informed by the principles of ethnographic
observation, with the research undertaking
prolonged periods of direct observation of how the
service is organised and delivered.
F. Qualitative interviews and focus groups with
representative groups of professionals and
participants to understand their shared and
distinct experiences of service delivery of each
form of rehabilitation.
All interview and focus group data will be analysed
following the conventions of framework analysis [32-34].
This is a hierarchical, matrix-based method developed
for applied or policy relevant qualitative research. It is a
highly structured, transparent and rigorous approach to
qualitative data which is well suited to research where
timescales are limited, and the goals of research are
clearly defined at the outset.Health economic study
The health economic study will undertake a within-trial
cost-effectiveness and cost utility analysis using estab-
lished methods [35]. The CIRACT service will be com-
pared to the THB-rehab service from a NHS and Personal
and Social Services (PSS) perspective in order to help in-
form commissioning decisions.
In addition to measuring the cost of the intervention,
the resources consumed in the two arms of the study
are likely to differ, as there is the potential for differential
equipment requests and differential lengths of stay in
hospital. Resources will be valued using published unit
cost data or where needed using locally derived unit
costs.Cost analysis
A detailed cost analysis of the two services to the NHS will
be considered from a time and motion study, and com-
pared against cost estimates based on standard methods
of collecting resource use information (here via a modified
Client Service Receipt Inventory (CSRI) questionnaire [27]
at baseline and at 91 days post-discharge). The detailed
micro-costing study will be conducted in three phases:
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review will provide information on how to conduct
the time and motion study (phase three).
2. Observation and semi-structured interviews (phase
two): Observations and interviews will provide
information on how to conduct the time and motion
study (phase three) and define what activities are
undertaken by each service. The observations of the
therapists will enable a greater understanding of
what each team offers and how they differ in their
service provision. This will allow comparisons to be
drawn between the two groups.
3. Micro-costing study (phase 3): using the information
from phase one and two a time and motion study
will be conducted with 10 patients in each arm,
recruited through purposive sampling, over a
six-month period. Within each treatment arm, we
will aim to include half of the participants with
baseline admission Barthel ADL of less than 14, and
the other half with a Barthel ADL of greater than
14, in order to ensure a wide range of abilities are
observed. The time and motion study will record
therapy interactions with the patient (face-to-face
and indirect) to enable costing of each service
provision. To get this data an RA will contact the
ward therapists or the CIRACT team (depending on
allocation) on a twice daily basis and ask how much
time they have spent in direct face-to-face contact
with the patient and indirectly, through non-face-to-
face contact (ward rounds, telephone calls, referrals,
and so forth).
To capture the contacts with therapists post-discharge,
the RA will establish from the therapists if they have
been referred on for further therapy and, if so, the con-
tact details of the community-based team. The RA will
then contact the treating therapist in the community to
gather contact time (non-face-to-face may then include
travel time) for two weeks following discharge. This will
provide us with the data required to cost the contact
time for each patient and enable comparisons between
groups. The specific activities undertaken by the thera-
pists with the patient will be explored through phase
two.Outcome measurement
We will use the EQ-5D-3 L and convert scores into
quality-adjusted life years (QALYs) using linear
interpolation and area under the curve methods for the
trial period [36]. We will adjust for any baseline differ-
ences between treatment groups [37]. The main out-
come for the cost utility analysis will therefore be
incremental cost per QALYs estimated from the changein EQ-5D-3 L score at baseline and at 91 days follow-up,
post-discharge.
Economic analysis
The results of the analysis will be presented using the in-
cremental cost effectiveness ratio (ICER), if appropriate,
with decision uncertainty represented via cost effective-
ness acceptability curves (CEACs) based on nonparamet-
ric bootstrapping of cost and effect pairs [38]. This will
provide robust results to inform decision-makers about
whether the NHS should provide the CIRACT service or
not compared to traditional care.
Data collection
Data will be collected using CIRACT trial data collec-
tion forms which will be monitored by the Nottingham
Clinical Trials Unit (NCTU) for consistency, validity and
quality. Missing data and data queries will be referred
promptly back to the recruiting site for clarification. If a
participant withdraws from the study, the data collected
up to that point will be used (as specified in the consent
form) but no further data will be collected about that
participant. Participants will not be replaced if they with-
draw from the study. All reasonable attempts will be
made to contact any participant lost to follow-up during
the course of the trial in order to complete assessments.
Data management
All trial data will be entered on a trial-specific database
with participants identified only by the unique trial
number, date of birth and initials. The database will be
developed and maintained by the trial coordinating
centre at the NCTU. Access to the database will be re-
stricted and secure. Data quality and compliance with
the protocol will be assessed throughout the trial by
verification of trial data against clinical records, and by
data checking for accuracy and internal consistency. For
the follow-up phase, identifiable information about par-
ticipants will be held in a separate database to the trial
anonymised data. Access to this information will be re-
stricted to those involved in the follow-up phase, as
authorised by the Chief Investigator.
Statistical analyses
The analysis and reporting of the trial will be in accord-
ance with the Consolidated Standards of Reporting
(CONSORT) guidelines. A full statistical analysis plan
will developed before any data are analysed. Appropriate
descriptive statistics will be used to compare the charac-
teristics of the randomised participants across the trial
groups. The primary approach to all comparative ana-
lyses will be based on treatment allocated without im-
putation of missing data. Between-group differences will
be estimated using regression models appropriate for
Watson et al. Trials  (2015) 16:41 Page 8 of 11outcome type, adjusting for baseline value of the outcome
if collected, and paying attention to 95% confidence inter-
vals as well as P values. Analysis of subgroups will be
agreed with the Trial Steering Committee and all those
undertaken will be reported.
Data monitoring
The day-to-day management of the trial is the responsibil-
ity of the Trial Manager, including research staff training
and management. Regular monitoring will be performed
by the trial Manager according to the Medical Research
Council (MRC) Guidelines for Good Clinical Practice
(GCP) in Clinical Trials (22). Following written standard
operating procedures, the Trial Manager or where re-
quired, a nominated designee of the Sponsor, will verify
that the clinical study is conducted and data are generated,
documented and reported in compliance with the pro-
tocol GCP guidelines and the applicable regulatory
requirements.
The study finance, documentation (such as assessment
forms and operating procedures), data recording and
storage is managed by the Trial Manager, who also mon-
itors progress and provides appropriate reports to the
Trial Steering Committee. The Principal Investigator will
instigate audits of procedures as required and takes
overall responsibility for any protocol changes through-
out the study.
As the trial is regarded as low risk, the Trial Steering
Committee will also act as the trial management group,
and the data monitoring committee. The group will be
chaired by the Principal Investigator, and will be com-
prised of investigators, research staff and patient repre-
sentatives and will monitors all aspects of the conduct
and progress of the trial, ensures that the protocol is ad-
hered to, and will take appropriate action to safeguard
participants and the quality of the trial.
In the case of an adverse event, the Trial Manager will
receive adverse event forms electronically and the group
will meet as required in the event of an excessive serious
adverse event rate, or if other information is reported to
it which raises concern over the safe conduct of the trial.
There is no plan for any interim analyses.
Harms
Data shall be collected for each individual participant
with regards to any fall that occurs whilst an inpatient
on the ward until time of discharge, and will be classed
as an ‘adverse event’. If the fall results in a fracture, con-
firmed by radiological findings, it will be classed as a ‘ser-
ious adverse event’. This was agreed by the Trial Steering
Committee. All serious adverse events will be reported to
the sponsor within 24 hours of knowledge of the event
using the adapted Nottingham University Hospitals NHS
Trust reporting forms made specific to this study. Theadverse event risks of taking part in the trial is minimal, as
the CIRACT service is not a different type of rehabilita-
tion, but a change in delivery of the THB-rehab service
the patients would receive as part of their usual care. The
CIRACT service has been assessed in a pilot study and no
adverse events occurred.
Ethics
This study has been given favourable opinion by NRES
Committee West Midlands- Staffordshire Research Ethics
Committee (REC Reference Number: 13/WM/0050) on
27 February 2013. The trial will be conducted in accord-
ance with ethical principles that have their origin in the
Declaration of Helsinki 1996, principles of good clin-
ical practice and the Department of Health Research
Governance Framework for Health and Social Care. Any
protocol amendments will be submitted to the trial spon-
sor and ethics committee. A register of protocol amend-
ments will be made available in the study protocol.
Confidentiality
Confidentiality of all participant information will be
maintained throughout the trial. Each participant will be
assigned a unique trial identification number (based on
their initials and recruitment number), allocated at ran-
domisation to be used for data collection forms, trial
documents and the trial database. Data collection forms
will be treated as confidential documents, and held se-
curely. The Chief Investigator is the custodian of the
data. Participants will not be identified in any future
publication.
Discussion
This article describes the protocol of a randomised trial
comparing the clinical and cost-effectiveness of the
THB-rehab service, with that of the CIRACT service.
The outcome of the study will influence clinical decision-
making, with respect to allocation of resources linked to
hospital discharge planning and re-admissions, in a very
resource intensive and growing group of patients.
The theoretical model underpinning the CIRACT ser-
vice has been based on the Medical Research Council
framework, funded by a Research and Development
Pump Priming Research award (Nottingham University
Hospitals Charitable funds) and re-ablement funding
stream (Nottingham City CCG).
Most early and/or supported discharge models in care
of the older person involve receiving patients back into
the community from hospital, with little or no direct in-
volvement in hospital-based rehabilitation. The novel as-
pect of the CIRACT intervention compared to other
models of care is that although the team will be based
on the hospital ward, they will be employed by a com-
munity NHS provider enabling the team to bring their
Watson et al. Trials  (2015) 16:41 Page 9 of 11community knowledge into the hospital care setting, in
addition to providing more intensive rehabilitation,
working closer with the patient and their relatives and
being able to facilitate and access a wider range of care
and services in the community. This is in contrast to the
hospital ward-based therapists, employed by the hospital,
who may not have the knowledge and direct and/or rapid
accessibility of care and services in the community.
From a financial and cost point of view, we know that
the NHS is facing unprecedented financial challenges
over the next few years. Therefore any new service re-
quires both clinical and cost-effectiveness evidence to
support decision-making. However, many research stud-
ies lack good quality costing or cost-effectiveness data,
and where studies have been published, average cost of
events are often assigned using national and centre-
specific price weights, which may not reflect true costs.
Micro-costing studies involve direct enumeration and
detailed costing of each input consumed [39] although
are infrequently undertaken in complex interventional
studies. Therefore, in addition to the clinical evaluation
of the CIRACT service, we propose to undertake a cost
and cost-effectiveness evaluation of this service delivery.
One of the main limitations of this study is that the
ward staff and participants cannot be blinded to the re-
habilitation group allocation as both services are pro-
vided within each ward. However, early pilot work [40]
demonstrated that participants and staff very quickly be-
come unaware of group allocation, presumably related
to the fluid nature of the ward environment and thatTable 1 Summary of major protocol amendments
Date of amendment Wording pre-amendment
14 October, 2013 Follow-up at day 91 post-discharge face-to-face
interviews by RA at participant’s home.
14 October, 2013 Follow-up to be completed at day 91 (+/− 3 days)
post-discharge.
14 October, 2013 Patients excluded at discharge will be excluded from
length of stay (LOS) analysis, but a sensitivity analysis
proxy LOS models will be used to check the robustn
the exclusion.
14 October, 2013 Additional paragraph.
10 March, 2014. We propose to conduct the trial on two wards which
give the required numbers within our proposed time
for the study.
10 March, 2014. Additional paragraph.much of the rehabilitation is undertaken away from the
bedside. Baseline data will be collected prior to random-
isation and outcome measures collected by a blinded RA
to minimize the risk of detection bias. A statistician
blind to group assignment will perform the data analysis.Patient and public involvement (PPI)
Members of the PPI advisory group will be present at
Trial Management Group (TMG) meetings and a service
user representative will be part of the Trial Steering
Committee. This patient and public involvement will
aim to provide guidance and advice from the patient
perspective.Dissemination policy
The trial will be reported according to the CONSORT
guidelines and will contribute to knowledge on the deliv-
ery of change across organisational systems, linkages be-
tween different care agencies and sectors and detailed
resource use and costing associated with complex inter-
ventions. Findings will be published in relevant periodi-
cals and updates sent to relevant websites such as the
Health Service Journal and the NHS Primary Care
Commissioning website. We will also undertake high-
impact conference presentations. Participants who re-
quested a copy of the report will be sent a lay summary
of the study. A publication policy will be agreed with co-
applicants and a systematic plan, including authorship,
for the peer-reviewed publications.Wording post-amendment
Follow-up at day 91 post-discharge.
Telephone or face-to-face interviews by RA at
participant’s home.
Follow-up to be completed at day 91 (−7/+28 days)
post- discharge.
the
using
ess of
The final intention-to-treat analysis will include all randomised
participants for whom the follow-up assessment of the primary
outcome measure is available. Per protocol analysis will include
all randomised participants who are deemed to have no
protocol violations.
Modified client services receipt inventory: GP practices may be
contacted by the research team to confirm visit data supplied
by the participant.
will
table
We propose to conduct the trial on two to three wards which
will give the required numbers within our proposed timetable
for the study.
The RA will contact the therapist involved with looking after
the patient at two time points during the day, from admission
onto the ward until the patient is discharged from the ward,
and continuing if applicable into the participant’s place of
residence for a period of two weeks Data collected will be
coded and entered into the database recording total time
spent with the patient (face-to-face and non-contact). A
summary of location codes will be extrapolated from phase two.
Watson et al. Trials  (2015) 16:41 Page 10 of 11Trial status
Recruitment to CIRACT commenced in June 2013 and is
ongoing at the time of manuscript submission. The ex-
pected time of recruitment completion is August 2014.
Major protocol amendments
Over the course of the trial a number of protocol
amendments were made as summarised in Table 1.
Additional file
Additional file 1: Schedule of enrolment, interventions and
assessments in the CIRACT trial.
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